A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic, were linked to a 33% lower risk of dementia.

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so. Meanwhile, Medicare currently covers GLP-1 drugs for people with a ...

Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

Congestion pricing turned six months old Saturday, and Gov. Kathy Hochul is boasting that the tolling program is reducing traffic in the city, among other benefits. The number of vehicles is down ...

Novo Nordisk's (NVO) downward guidance Tuesday sent its stock diving 20%, even as new leadership remains bullish on the company's ability to maintain a market lead in the obesity drug space. The maker ...

What does it take to buy a typical single-family home in Greater Boston? $1 million. That’s according to the Greater Boston Association of Realtors, which released June sales data covering most ...

Biochemist Svetlana Mojsov, honored for GLP-1 research that has transformed metabolic disease care, says she’s grateful to have contributed to something that’s helped so many.

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs other antidiabetic drugs, a new study shows.

GLP-1 weight-loss drugs are changing how people date and connect. In a nationally representative survey of 2,000 single U.S. adults (ages 18 to 91) led by the Kinsey Institute at Indiana ...

Uncover high quality GLP-1 therapy tools used to develop blood sugar control and weight loss medications.